Optimizing Effect Sizes With Imaging Enrichment and Outcome Choices for Mild Alzheimer Disease Clinical Trials.

about

Optimizing Effect Sizes With Imaging Enrichment and Outcome Choices for Mild Alzheimer Disease Clinical Trials.

Item

http://www.wikidata.org/entity/Q39753296

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Optimizing Effect Sizes With I ...... eimer Disease Clinical Trials.

@en

Optimizing Effect Sizes With I ...... eimer Disease Clinical Trials.

@nl

type

Item

label

Optimizing Effect Sizes With I ...... eimer Disease Clinical Trials.

@en

Optimizing Effect Sizes With I ...... eimer Disease Clinical Trials.

@nl

prefLabel

Optimizing Effect Sizes With I ...... eimer Disease Clinical Trials.

@en

Optimizing Effect Sizes With I ...... eimer Disease Clinical Trials.

@nl

P1476

Optimizing Effect Sizes With I ...... eimer Disease Clinical Trials.

@en

P2093

David Elashoff

http://www.w3.org/2001/XMLSchema#string

Edmond Teng

http://www.w3.org/2001/XMLSchema#string

Joshua D Grill

http://www.w3.org/2001/XMLSchema#string

Timothy S Chang

http://www.w3.org/2001/XMLSchema#string

P2860

In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)

Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

P304

19-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/WAD.0000000000000150

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alzheimer's Disease Neuroimaging Initiative

P577

2016-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27196535

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

5116001

http://www.w3.org/2001/XMLSchema#string